CRISPR: The Actual State of Gene Editing in 2025

# CRISPR: The Actual State of Gene Editing in 2025

CRISPR-Cas9 got into the popular press as a "revolution" in genetic editing around 2013. The coverage was not wrong — it really was a significant technical advance — but it generated expectations that the actual science has been walking back ever since. Here's the weird part: CRISPR is genuinely powerful and genuinely limited, often in ways that the enthusiastic coverage didn't make clear.

Let's be specific about what it can do, what it can't, and where the real clinical progress has actually happened.

## What CRISPR Actually Does

The Cas9 enzyme works as a programmable molecular scissor. You design a guide RNA that matches a specific DNA sequence, the guide RNA leads Cas9 to that sequence, and Cas9 cuts both strands of the DNA double helix. The cell's repair machinery then tries to fix the cut. There are two main repair pathways: NHEJ (non-homologous end joining), which is error-prone and usually disrupts or disables the gene at the cut site, and HDR (homology-directed repair), which can be used to make precise edits if you provide a template, but which is much less efficient.

> 🔬 Quick experiment: Think of CRISPR like a search-and-cut tool in a word processor. You can find a specific word and delete it (NHEJ path) fairly reliably. Replacing it with a specific new word (HDR path) is harder — the "paste" doesn't always work, and sometimes other things get cut accidentally.

This matters clinically. NHEJ-based gene disruption — knocking out a problematic gene — is considerably more tractable than precise gene correction. Most of the successful clinical applications use disruption.

## What's Actually Approved and Working

The first CRISPR-based therapy received FDA and EMA approval in late 2023: Casgevy (exagamglogene autotemcel), developed by Vertex and CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta-thalassemia. This is real. It works. Initial clinical data shows that the vast majority of treated patients are transfusion-free after a single treatment.

But it's important to understand what this therapy actually does. It doesn't correct the disease-causing mutation. It uses CRISPR to disrupt the gene that suppresses fetal hemoglobin in adult cells — essentially reactivating a switch that was turned off during development. The therapy works around the mutation rather than fixing it. That's a technically elegant solution and clinically meaningful, but it's not the "edit any gene you want" capability that the initial coverage often implied.

Intellia Therapeutics and Regeneron have published promising data on in vivo CRISPR for transthyretin amyloidosis, a rare but serious disease caused by protein misfolding. Other clinical programs for various conditions are progressing through trials. The pipeline is real.

## The Off-Target Problem

The most persistent technical challenge is off-target editing: Cas9 sometimes cuts at sequences similar to the target sequence rather than just the target. For a therapy intended to last a patient's lifetime, unintended edits in unintended locations are a serious safety concern.

The field has made real progress on this. High-fidelity Cas9 variants have substantially reduced off-target cutting rates. Base editing and prime editing — newer tools that can make precise single-letter changes in DNA without making double-strand cuts — reduce off-target risk further and have better efficiency for precise edits. But "substantially reduced" is not the same as "eliminated," and the long-term safety monitoring is still accumulating.

## The Delivery Problem

Here's a limitation that doesn't get enough coverage: getting the editing machinery into the right cells in a living body is genuinely hard. Current approaches include ex vivo editing (remove cells, edit outside the body, reinfuse — works for blood diseases, doesn't work for most other tissues), lipid nanoparticles (effective for the liver), and viral vectors (AAV can reach many tissues but has payload size limits and immunogenicity concerns).

The liver is relatively easy to reach. Brain, muscle, and many other tissues are much harder. This is a core reason why CRISPR-based therapies are currently concentrated in blood diseases and liver conditions.

## Where the Hype Was Wrong

The popular coverage in 2013–2018 implied that CRISPR would enable us to precisely correct any genetic mutation causing any disease within the foreseeable future. The reality is: most disease-causing genetic variants aren't single-letter mutations you can simply correct — many are large deletions, duplications, or complex rearrangements. Many conditions are caused by hundreds of different mutations in the same gene, requiring individualized approaches. Many more conditions are polygenic (caused by many genes interacting), not amenable to single-edit solutions. And delivery remains a fundamental bottleneck for anything beyond liver and blood.

CRISPR is a genuinely transformative tool. The approved therapy for sickle cell disease is a real clinical achievement for patients who had no other options. The pipeline includes real science addressing real diseases. But "transformative" and "solves genetic disease broadly" are very different claims, and the gap between them has been doing a lot of work in public understanding.

CRISPR: The Actual State of Gene Editing in 2025

// COMMENTS

ON THIS PAGE